The Invisiport offers a less invasive, patient-friendly alternative to traditional chest ports and peripherally inserted central catheters (PICCs). It is intended to be used in patients needing long-term intravenous treatment such as cancer, infection or other diseases.
Stealths Invisiport product provides the same function as conventional implanted ports, but features a patented self-deploying wing that minimizes insertion size and supports stability once implanted in a patients arm, attributes that are mutually exclusive in existing devices. Patients can benefit from a smaller incision. With the smaller incision requirement, the Invisiport may allow a shorter implant procedure time.
"The FDAs clearance of our unique Invisiport product is an important milestone for the company," said Peter Drumm, Stealth Therapeutics CEO. "We look forward to raising additional capital to support our commercialization effort and the continued development of several additional products in the companys pipeline. We remain focused on creating value for patients, medical professionals and investors through innovative vascular access device products that improve patient experiences and reduce costs."
Stealth Therapeutics FDA submission and commercialization work has been supported by the Kegonsa Seed Fund, Wisconsins premier seed venture capital fund operated by Ken Johnson. The fund has invested in 12 other start-up companies, including Jellyfish, Alice.com, and Networked Insights.
About Stealth Therapeutics Inc.
Stealth Therapeutics was founded in 2006 for the purpose of designing and developing a portfolio of improved venous access devices. The technology is derived from the clinical practice of the companys founder, Dr. Bradley Glenn. Dr. Glenn, a practicing interventional radiologist with strong interest and experience in venous access devices, guides Stealth Therapeutics product strategy. For more information about the company, please visit www.stealththerapeutics.com.